{"nctId":"NCT00039741","briefTitle":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","startDateStruct":{"date":"2002-08"},"conditions":["HIV Infections"],"count":266,"armGroups":[{"label":"PI/1K","type":"EXPERIMENTAL","interventionNames":["Drug: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)","Drug: PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)"]},{"label":"NNRTI/1K","type":"EXPERIMENTAL","interventionNames":["Drug: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)","Drug: NNRTIs (EFV, NVP)"]},{"label":"PI/30K","type":"EXPERIMENTAL","interventionNames":["Drug: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)","Drug: PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)"]},{"label":"NNRTI/30K","type":"EXPERIMENTAL","interventionNames":["Drug: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)","Drug: NNRTIs (EFV, NVP)"]}],"interventions":[{"name":"NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)","otherNames":["2 NRTIs/PI, change@viral load 1000 copies/ml or higher","2 NRTIs/PI, change@viral load 30,000 copies/ml or higher","2 NRTIs/NNRTI, change@viral load 1000 copies/ml or higher","2 NRTIs/NNRTI, change@viral load 30,000 copies/ml or higher"]},{"name":"NNRTIs (EFV, NVP)","otherNames":["2 NRTIs/NNRTI, change@viral load 1000 copies/ml or higher","2 NRTIs/NNRTI, change@viral load 30,000 copies/ml or higher"]},{"name":"PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)","otherNames":["2 NRTIs/PI, change@viral load 1000 copies/ml or higher","2 NRTIs/PI, change@viral load 30,000 copies/ml or higher"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Older than 30 days and younger than 18 years of age (may enroll up to the day before their 18th birthday)\n* HIV infected\n* Not previously on HAART or received anti-HIV drugs for less than 56 consecutive days after birth to prevent mother-to-infant HIV transmission. Participants who have previously received nevirapine for the prevention of mother-to-infant HIV transmission are not eligible for this study.\n* Willing to use acceptable methods of contraception\n\nExclusion Criteria:\n\n* Grade 3 or 4 clinical or laboratory toxicity. More information on this criterion can be found in the protocol.\n* Active opportunistic infection or a serious bacterial infection at the time of study entry\n* Pancreas, nervous system, blood, liver, or kidney problems that make it impossible to take study medications\n* Taking any medication that cannot be combined with the study medications in first-line therapy\n* Received therapy for cancer\n* Pregnant or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Days","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Viral Load Measured in log10 HIV-1 RNA Copies/ml","description":null,"paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.16","spread":"0.09"},{"groupId":"OG001","value":"-3.31","spread":"0.09"},{"groupId":"OG002","value":"-3.26","spread":"0.09"},{"groupId":"OG003","value":"-3.20","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Rate of Grade 3 or Higher Signs, Symptoms, or Laboratory Abnormalities Experienced","description":"Adverse events were graded according to the following guidelines:\n\nPACTG: \"The Manual for Expedited Reporting of Adverse Events to DAIDS\" (DAIDS EAE Manual) dated May 6, 2004.\n\nPENTA: International Conference for Harmonization (ICH) requirements and the EU Clinical Trials Directive 2001/20/EC (20).\n\nA rating of Grade 3 is severe and Grade 4 is life-threatening. The rate of serious (Grade 3 or above)events is reported as the number of events per 100 child/years.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":null},{"groupId":"OG001","value":"0.17","spread":null},{"groupId":"OG002","value":"0.16","spread":null},{"groupId":"OG003","value":"0.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Significant HIV-related Clinical Events, Defined as CDC Category C (AIDS Defining) Diagnoses (Except for Recurrent Bacterial Infections)or Death","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Switching to an Alternative Class ART Regimen (Based on Initial Randomized Regimen)","description":"25th Percentiles in weeks from randomization to starting an alternative class ART regimen (based on initial randomized regimen)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to HIV-1 RNA of 400 Copies/ml or Greater During First-line Therapy or Permanent Discontinuation of First-line Therapy","description":"25th Percentiles in weeks from randomization HIV-1 RNA of 400 copies/ml or greater during first-line therapy or permanent discontinuation of first-line therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"72","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to HIV-1 RNA of 30,000 Copies/ml or Greater During Second-line Therapy or Permanent Discontinuation of Second-line Therapy","description":"25th Percentiles in weeks from randomization to HIV-1 RNA of 30,000 copies/ml or greater during second-line therapy or permanent discontinuation of second-line therapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"267","spread":null},{"groupId":"OG003","value":"228","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Children With an HIV-1 RNA Level Less Than 400 Copies/ml Regardless of Therapy at Week 204","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in CD4% From Randomization to 4 Years","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":"0.8"},{"groupId":"OG001","value":"15.2","spread":"0.8"},{"groupId":"OG002","value":"15.1","spread":"0.8"},{"groupId":"OG003","value":"13.9","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Number of Children With HIV-1 RNA Less Than 400 Copies/ml and on Original Randomized Therapy at 24 Weeks","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"91","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":66},"commonTop":[]}}}